Sarmad Sadeghi, Samuel Callis, Primo N. Lara, Stephanie A. Berg, Jason Robert Brown, Adanma Ayanambakkam, Suzanne Cole, Elizabeth R. Kessler, Daniel A. Vaena, Greg R. Angstreich, Theodore Stewart Gourdin, Nataliya Mar, Rick Bangs, Darrell Nakagawa, Siamak Daneshmand, Ian Murchie Thompson, Thomas W. Flaig, Daniel P. Petrylak, Seth P. Lerner. "A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.tps894